The War on Psychedelics: Why Psilocybin's "Medicinal" Status Isn't Enough
In a groundbreaking study, the Scottsdale Research Institute has announced its intention to use psilocybin mushrooms in treating post-traumatic stress disorder (PTSD), a move that highlights the growing body of research into the psychotherapeutic potential of a substance that has been federally prohibited since 1968. However, while this initiative may mark a step towards recognizing psilocybin's medicinal benefits, it falls short of addressing the glaring injustice of criminalizing people who use psychedelics for reasons deemed unworthy by the government.
The FDA has recognized psilocybin as a "breakthrough therapy" for treatment-resistant depression and has shown promise in treating cancer-related anxiety. However, the lengthy process of obtaining FDA approval remains expensive and time-consuming, with no new options emerging in years. In contrast, Oregon's 2018 ballot initiative authorized state-licensed "psilocybin service centers," allowing adults to use the substance under supervision, without requiring a medical or psychiatric diagnosis.
This more permissive approach has led to decriminalization initiatives in Colorado and local measures discouraging arrest and prosecution of psychedelic users. The language used by these campaigns β describing psilocybin as an "entheogen" that generates "the god within" β suggests that the substance's value extends beyond purely psychiatric applications.
Research has shown that people who have used psilocybin report a range of goals, including improved mental health, personal development, spiritual growth, and cognitive enhancement. While these motivations may not fit neatly into any FDA-approved application, they highlight the complex and multifaceted nature of psychedelic experiences.
The federal laws surrounding psilocybin are particularly egregious, with possession punishable by up to 20 years in prison. These harsh penalties serve no purpose other than to criminalize personal choices deemed "frivolous" by policymakers, rather than addressing any real or perceived harm caused by the substance.
Ultimately, the war on psychedelics must be reexamined. Rather than treating people's use of these substances as crimes, we should recognize their value in promoting mental health, personal growth, and spiritual exploration. By decriminalizing psilocybin and other natural psychedelics, we can begin to address the systemic injustices that have been imposed upon individuals seeking to harness its therapeutic potential.
In a groundbreaking study, the Scottsdale Research Institute has announced its intention to use psilocybin mushrooms in treating post-traumatic stress disorder (PTSD), a move that highlights the growing body of research into the psychotherapeutic potential of a substance that has been federally prohibited since 1968. However, while this initiative may mark a step towards recognizing psilocybin's medicinal benefits, it falls short of addressing the glaring injustice of criminalizing people who use psychedelics for reasons deemed unworthy by the government.
The FDA has recognized psilocybin as a "breakthrough therapy" for treatment-resistant depression and has shown promise in treating cancer-related anxiety. However, the lengthy process of obtaining FDA approval remains expensive and time-consuming, with no new options emerging in years. In contrast, Oregon's 2018 ballot initiative authorized state-licensed "psilocybin service centers," allowing adults to use the substance under supervision, without requiring a medical or psychiatric diagnosis.
This more permissive approach has led to decriminalization initiatives in Colorado and local measures discouraging arrest and prosecution of psychedelic users. The language used by these campaigns β describing psilocybin as an "entheogen" that generates "the god within" β suggests that the substance's value extends beyond purely psychiatric applications.
Research has shown that people who have used psilocybin report a range of goals, including improved mental health, personal development, spiritual growth, and cognitive enhancement. While these motivations may not fit neatly into any FDA-approved application, they highlight the complex and multifaceted nature of psychedelic experiences.
The federal laws surrounding psilocybin are particularly egregious, with possession punishable by up to 20 years in prison. These harsh penalties serve no purpose other than to criminalize personal choices deemed "frivolous" by policymakers, rather than addressing any real or perceived harm caused by the substance.
Ultimately, the war on psychedelics must be reexamined. Rather than treating people's use of these substances as crimes, we should recognize their value in promoting mental health, personal growth, and spiritual exploration. By decriminalizing psilocybin and other natural psychedelics, we can begin to address the systemic injustices that have been imposed upon individuals seeking to harness its therapeutic potential.